SEARCH

SEARCH BY CITATION

References

  • 1
    Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 2: 6534.
  • 2
    Drossman DA. The functional gastrointestinal disorders and the Rome II process. Gut 1999; 45(Suppl. 2): II15.
  • 3
    Lynn RB, Friedman LS. Irritable bowel syndrome. N Engl J Med 1993; 329: 19405.
  • 4
    Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997; 112: 212037.
  • 5
    Talley NJ. Irritable bowel syndrome: definition, diagnosis and epidemiology. Baillieres Best Pract Res Clin Gastroenterol 1999; 13: 37184.
  • 6
    Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology 1990; 99: 40915.
  • 7
    Everhart JE, Go VL, Johannes RS, Fitzsimmons SC, Roth HP, White LR. A longitudinal survey of self-reported bowel habits in the United States. Dig Dis Sci 1989; 34: 115362.
  • 8
    Sandler RS, Drossman DA, Nathan HP, McKee DC. Symptom complaints and health care seeking behavior in subjects with bowel dysfunction. Gastroenterology 1984; 87: 3148.
  • 9
    Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38: 156980.
  • 10
    Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002; 122: 150011.
  • 11
    El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 2002; 16: 117185.
  • 12
    Horwitz BJ, Fisher RS. The irritable bowel syndrome. N Engl J Med 2001; 344: 184650.
  • 13
    Camilleri M, Williams DE. Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures. Pharmacoeconomics 2000; 17(4): 3318.
  • 14
    Jacobs P. The Economics of Health and Medical Care. Rockville, MD: Aspen Publishers, 1991.
  • 15
    Schramm C. Health Care and its Costs. New York: Norton, 1987.
  • 16
    Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991; 100: 9981005.
  • 17
    Talley NJ, Zinsmeister AR, Melton LJ 3rd. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995; 142: 7683.
  • 18
    Camilleri M. Management of the irritable bowel syndrome. Gastroenterology 2001; 120(3): 65268.
  • 19
    Finkler SA. The distinction between cost and charges. Ann Intern Med 1982; 96: 1029.
  • 20
    Lundberg GD. Costs, charges, conscience, and control (lost). J Am Med Assoc 1983; 250: 2509.
  • 21
    Price KF. Pricing Medicare's diagnosis-related groups: charges versus estimated costs. Health Care Financ Rev 1989; 11: 7990.
  • 22
    Oxman AD, Cook DJ, Guyatt GH. Users' guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group. J Am Med Assoc 1994; 272: 136771.
  • 23
    Guyatt GH, Sinclair J, Cook DJ, Glasziou P. Users' guides to the medical literature. XVI. How to use a treatment recommendation. Evidence-Based Medicine Working Group and the Cochrane Applicability Methods Working Group. J Am Med Assoc 1999; 281: 183643.
  • 24
    Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995; 109(6): 173641.
  • 25
    Coremans G, Dapoigny M, Muller-Lissner S, et al. Diagnostic procedures in irritable bowel syndrome. Digestion 1995; 56(1): 7684.
  • 26
    Wells NE, Hahn BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11(6): 101930.
  • 27
    Bentkover JD, Field C, Greene EM, Plourde V, Casciano JP. The economic burden of irritable bowel syndrome in Canada. Can J Gastroenterol 1999; 13(Suppl. A): 89A96A.
  • 28
    Levy RL, Whitehead WE, Von Korff MR, Feld AD. Intergenerational transmission of gastrointestinal illness behavior. Am J Gastroenterol 2000; 95(2): 4516.
    Direct Link:
  • 29
    Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001; 96(11): 31229.
    Direct Link:
  • 30
    Creed F, Ratcliffe J, Fernandez L, et al. Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome. Ann Intern Med 2001; 134(9): 8608.
  • 31
    Suleiman S, Sonnenberg A. Cost-effectiveness of endoscopy in irritable bowel syndrome. Arch Intern Med 2001; 161(3): 36975.
  • 32
    Patel R, Petitta A, Fogel R, Peterson E, Zarowitz B. The economic impact of irritable bowel syndrome in a managed care setting. J Clin Gastroenterol 2002; 35: 1420.
  • 33
    Akehurst RL, Brazier JE, Mathers N, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002; 20: 45562.
  • 34
    Houghton LA, Heyman DJ, Whorwell PJ. Symptomatology, quality of life and economic features of irritable bowel syndrome—the effect of hypnotherapy. Aliment Pharmacol Ther 1996; 10(1): 915.
  • 35
    Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.